ATE256469T1 - Materialien zur behandlung von zuständen, bei denen basophile- oder eosinophile-granulozyten oder mastzellen eine rolle spielen - Google Patents

Materialien zur behandlung von zuständen, bei denen basophile- oder eosinophile-granulozyten oder mastzellen eine rolle spielen

Info

Publication number
ATE256469T1
ATE256469T1 AT99913481T AT99913481T ATE256469T1 AT E256469 T1 ATE256469 T1 AT E256469T1 AT 99913481 T AT99913481 T AT 99913481T AT 99913481 T AT99913481 T AT 99913481T AT E256469 T1 ATE256469 T1 AT E256469T1
Authority
AT
Austria
Prior art keywords
ipgs
mast cells
ipg
basophilic
role
Prior art date
Application number
AT99913481T
Other languages
English (en)
Inventor
Thomas William Rademacher
Helen Whitby
Original Assignee
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London filed Critical Univ London
Application granted granted Critical
Publication of ATE256469T1 publication Critical patent/ATE256469T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99913481T 1998-03-27 1999-03-29 Materialien zur behandlung von zuständen, bei denen basophile- oder eosinophile-granulozyten oder mastzellen eine rolle spielen ATE256469T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806645.9A GB9806645D0 (en) 1998-03-27 1998-03-27 Materials and methods relating to the treatment of conditions involving mast cells,basophils and eosinophils
PCT/GB1999/000981 WO1999049855A2 (en) 1998-03-27 1999-03-29 Ipg antagonists for the treatment of conditions involving mast cells, basophils and eosinophils

Publications (1)

Publication Number Publication Date
ATE256469T1 true ATE256469T1 (de) 2004-01-15

Family

ID=10829426

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99913481T ATE256469T1 (de) 1998-03-27 1999-03-29 Materialien zur behandlung von zuständen, bei denen basophile- oder eosinophile-granulozyten oder mastzellen eine rolle spielen

Country Status (10)

Country Link
US (1) US20040141973A1 (de)
EP (1) EP1066043B1 (de)
JP (1) JP2004500309A (de)
AT (1) ATE256469T1 (de)
AU (1) AU754132B2 (de)
CA (1) CA2319588A1 (de)
DE (1) DE69913670T2 (de)
ES (1) ES2213359T3 (de)
GB (1) GB9806645D0 (de)
WO (1) WO1999049855A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0015625D0 (en) * 2000-06-26 2000-08-16 Univ London Materials and methods relating for the treatment and diagnosis of pre-eclampsia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9505658D0 (en) * 1995-03-21 1995-05-10 Univ London Hormone and growth factor mimetics
GB9618931D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in pre-eclampsia and diabetes
GB9618934D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
GB9618929D0 (en) * 1996-09-11 1996-10-23 Univ London Metal containing carbohydrates from human tissue which regulate glycogen metabolism
GB9618930D0 (en) * 1996-09-11 1996-10-23 Univ London Metal containing carbohydrates from human tissue which regulate lipogenic activity

Also Published As

Publication number Publication date
DE69913670D1 (de) 2004-01-29
GB9806645D0 (en) 1998-05-27
WO1999049855A3 (en) 1999-11-18
CA2319588A1 (en) 1999-10-07
EP1066043B1 (de) 2003-12-17
JP2004500309A (ja) 2004-01-08
ES2213359T3 (es) 2004-08-16
WO1999049855A2 (en) 1999-10-07
AU754132B2 (en) 2002-11-07
EP1066043A2 (de) 2001-01-10
DE69913670T2 (de) 2004-10-21
US20040141973A1 (en) 2004-07-22
AU3159699A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
GB9501683D0 (en) Substances and their uses
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
ATE403437T1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
DE60043308D1 (de) Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
DE60043397D1 (de) Cytokine, insbesondere tnf-alpha, hemmer
BR0107943A (pt) Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2005000215A3 (en) Methods for treating pain
DE69323768T2 (de) Pyrrolopyrimidine als crf antagonisten
ATE297755T1 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
UA74325C2 (uk) ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ р38, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇХ МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ ЗА ЇХ ДОПОМОГОЮ
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
ATE481101T1 (de) Verfahren zur behandlung von angstzuständen
ATE348812T1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
WO2002091858A8 (en) Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
ATE343398T1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
EP0577025A3 (de) Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
WO2002098362A3 (en) Use of rank antagonists to treat cancer
WO2004037165A3 (en) Nitric oxide and its biomedical significance
ATE256469T1 (de) Materialien zur behandlung von zuständen, bei denen basophile- oder eosinophile-granulozyten oder mastzellen eine rolle spielen
WO2004091558A3 (en) Compounds for stimulating and for inhibiting melanin formation, and methods for screening these compounds
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
ATE420636T1 (de) Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties